OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0000707511

REGENERX BIOPHARMACEUTICALS INC

REGENERX BIOPHARMACEUTICALS INC (CIK 0000707511, EIN 52-1253406) reported revenue of $76,761 for FY2022 (2022-01-01 to 2022-12-31) and net income of -$1.73 million (-$1,727,455) for FY2022 (2022-01-01 to 2022-12-31), as filed in its 10-K filed 2023-04-11 (accession 0001410578-23-000628).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0000707511
EIN52-1253406
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_6s55kq5ch3mwhbh7z9rcbb2mbc
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$76,761FY20222022-01-01 to 2022-12-3110-K2023-04-110001410578-23-000628Revenues
Net income-$1,727,455FY20222022-01-01 to 2022-12-3110-K2023-04-110001410578-23-000628NetIncomeLoss
Total assets$382,177FY2022as of 2022-12-3110-K2023-04-110001410578-23-000628Assets
Total liabilities$3,827,648FY2022as of 2022-12-3110-K2023-04-110001410578-23-000628Liabilities
Stockholders' equity-$3,445,471FY2022as of 2022-12-3110-K2023-04-110001410578-23-000628StockholdersEquity
Operating cash flow-$940,718FY20222022-01-01 to 2022-12-3110-K2023-04-110001410578-23-000628NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$0.01 per shareFY20222022-01-01 to 2022-12-3110-K2023-04-110001410578-23-000628EarningsPerShareDiluted
Shares outstanding143,549,735 sharesFY2022as of 2023-03-1710-K2023-04-110001410578-23-000628EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2013-2022, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20222022-01-01 to 2022-12-31$76,76110-K2023-04-110001410578-23-000628
RevenueFY20212021-01-01 to 2021-12-31$76,76110-K2023-04-110001410578-23-000628
RevenueFY20202020-01-01 to 2020-12-31$76,76110-K2022-03-300001104659-22-040167
RevenueFY20192019-01-01 to 2019-12-31$76,76210-K2021-03-020001104659-21-030728
RevenueFY20182018-01-01 to 2018-12-31$69,66710-K2020-03-200001104659-20-036901
RevenueFY20172017-01-01 to 2017-12-31$56,65210-K2019-03-290001144204-19-016982
RevenueFY20162016-01-01 to 2016-12-31$93,30810-K2018-03-290001144204-18-017995
RevenueFY20152015-01-01 to 2015-12-31$60,61210-K2017-03-290001144204-17-017360
RevenueFY20142014-01-01 to 2014-12-31$010-K2016-04-110001144204-16-093682
Net incomeFY20222022-01-01 to 2022-12-31-$1,727,45510-K2023-04-110001410578-23-000628
Net incomeFY20212021-01-01 to 2021-12-31-$1,597,75510-K2023-04-110001410578-23-000628
Net incomeFY20202020-01-01 to 2020-12-31-$1,523,36810-K2022-03-300001104659-22-040167
Net incomeFY20192019-01-01 to 2019-12-31-$1,404,24710-K2021-03-020001104659-21-030728
Net incomeFY20182018-01-01 to 2018-12-31-$1,993,55310-K2020-03-200001104659-20-036901
Net incomeFY20172017-01-01 to 2017-12-31$286,48710-K2019-03-290001144204-19-016982
Net incomeFY20162016-01-01 to 2016-12-31$229,12510-K2018-03-290001144204-18-017995
Net incomeFY20152015-01-01 to 2015-12-31-$5,270,48310-K2017-03-290001144204-17-017360
Net incomeFY20142014-01-01 to 2014-12-31-$2,753,64210-K2016-04-110001144204-16-093682
Net incomeFY20132013-01-01 to 2013-12-31-$671,34310-K2015-03-310001144204-15-020097

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2023-05-152023-03-310001410578-23-001223rgrx-20230331x10q.htm
10-K2023-04-112022-12-310001410578-23-000628rgrx-20221231x10k.htm
10-Q2022-11-142022-09-300001410578-22-003350rgrx-20220930x10q.htm
10-Q2022-08-122022-06-300001410578-22-002406rgrx-20220630x10q.htm
10-Q2022-05-162022-03-310001410578-22-001705rgrx-20220331x10q.htm
10-K2022-03-302021-12-310001104659-22-040167rgrx-20211231x10k.htm
10-Q2021-11-152021-09-300001104659-21-139207rgrx-20210930x10q.htm
10-Q2021-08-062021-06-300001104659-21-101442rgrx-20210630x10q.htm
10-Q2021-05-142021-03-310001104659-21-066826tm2111763d1_10q.htm
10-K2021-03-022020-12-310001104659-21-030728tm211107d1_10k.htm
10-Q2020-11-132020-09-300001104659-20-125049tm2029890d1_10q.htm
10-Q2020-08-142020-06-300001104659-20-095495tm2020419-1_10q.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0000707511published by the sourcedata.sec.gov/submissions/CIK0000707511.json2026-10-21
Employer Identification Number (EIN) · US-EIN52-1253406published by the sourcedata.sec.gov/submissions/CIK0000707511.json2026-10-21

Former names

NameFromTo
ALPHA 1 BIOMEDICALS INC1995-12-282001-05-11
ALPHA 1 BIOMEDICALS INC /DE/1994-03-091995-02-07

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0000707511.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0000707511.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000707511" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000707511/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000707511/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"707511"}

On SEC EDGAR

About this data